ArticleInternational journal of cancer2026
Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
Circulating tumor cells (CTCs) are valuable liquid biopsy analytes as they facilitate an in-depth characterization of disseminated tumors by a simple blood draw. Most CTC assays can only process limited blood volumes, potentially hampering the detection of cells of very low frequency, such as CTCs. Here, we introduce a novel, functionalized nickel filtration membrane, facilitating rapid enrichment of CTCs from various volumes of blood up to 40 mL and leukapheresis products. We validated this assay with different cancer cell lines and compared the performance of our new assay with that of the FDA-cleared CellSearch® system. Performing a comparative analysis of 20 blood samples from patients with metastatic breast cancer, CTCs were found in 19/20 patients (95%), combining the results of both CTC enrichment assays. CTC counts/7.5 mL of blood ranged from 0 to 7280 (CTC filtration membrane) and 0 to 17,190 (CellSearch®). Applying the clinically relevant cut-off of ≥5 CTCs/7.5 mL of blood, 19/20 samples processed with our CTC filter were categorized identically to those analyzed with the CellSearch® system. Furthermore, the filtration time of 40 s for 7.5 mL of blood represents an important advantage of our system, compared to other systems. Importantly, we also demonstrated the feasibility of processing blood samples of up to 40 mL or 2 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.